secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZEVRA THERAPEUTICS, INC. (ZVRA)
CIK:        0001434647
Form:       8-K
Filed at:   2025-11-20T23:59:59+00:00
Accession:  0001193125-25-289865
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zevra Therapeutics CFO R. LaDuane Clifton resigns effective Dec 31, 2025
------------------------------------------------------------------------

- CFO Clifton to depart Dec 31, 2025 to pursue other professional opportunities.
- Separation benefits: 12 months base salary, 40% annual bonus, COBRA, full equity vesting.
- Company has initiated search for new CFO; Neil F. McFarlane thanked Clifton for his leadership.
- Clifton played role in company's transition from development to commercial-stage rare disease firm.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434647/000119312525289865/0001193125-25-289865-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434647/000119312525289865/d78999d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-289865

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer